Alkylating agent linked to therapy-related leukemia

Alkylating agent linked to therapy-related leukemia
For patients treated for Hodgkin's lymphoma, cumulative doses of alkylating agent is associated with the risk of therapy-related acute myeloid leukemia/myelodysplastic syndrome, according to a study published online Jan. 7 in the Journal of Clinical Oncology.

(HealthDay)—For patients treated for Hodgkin's lymphoma (HL), cumulative doses of alkylating agent (AA) is associated with the risk of therapy-related acute myeloid leukemia/myelodysplastic syndrome (t-AML/MDS), according to a study published online Jan. 7 in the Journal of Clinical Oncology.

Michael Zach Koontz, M.D., from the Stanford University Medical Center in California, and colleagues reviewed the records of 754 patients with HL (treated from 1974 to 2003) with at least five years of follow-up after completing therapy in successive generations of Stanford clinical trials. S studies (1974 to 1980) and C studies (1981 to 1989) utilized extended-field , while G studies (1989 to 2003) utilized involved-field radiotherapy. Primary chemotherapies varied by study.

The researchers found that, in the G studies, the cumulative exposure to AA was substantially lower than in the S and C studies, with a 75 to 83 percent lower dose of nitrogen mustard and omission of procarbazine and . t-AML/MDS developed in 24 patients, 15 following primary chemotherapy and nine after salvage for relapsed HL. G studies had a significantly lower incidence of t-AML/MDS (0.3 percent) compared with the S (5.7 percent) or C (5.2 percent) studies. No t-AML/MDS was seen in G studies after primary therapy. No patient from the G studies developed t-AML-MDS after primary therapy; t-AML/MDA developed in one patient from the G studies following second-line therapy.

"Our data demonstrate the relationship between the cumulative AA dose and t-AML/MDS," the authors write. "The prognosis for t-AML/MDS is dismal, and it is imperative that therapies minimize these risks."

One author disclosed financial ties to the pharmaceutical industry.

More information: Abstract
Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

No higher risk of acute leukaemia in close relatives

Dec 15, 2011

(Medical Xpress) -- Parents, siblings and children of patients with the most common form of acute leukemia do not run a higher risk of developing the disease as was once believed, according to a new study from the Swedish ...

Recommended for you

Unraveling the 'black ribbon' around lung cancer

12 hours ago

It's not uncommon these days to find a colored ribbon representing a disease. A pink ribbon is well known to signify breast cancer. But what color ribbon does one think of with lung cancer?

User comments